Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.30% | -1.67% | 8.35% | 88.34% | 87.32% |
| Total Depreciation and Amortization | 218.57% | 5,575.00% | -69.97% | -89.60% | -96.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.99% | 23.47% | 16.15% | -99.45% | -99.46% |
| Change in Net Operating Assets | -165.20% | -295.30% | 66.14% | -11.66% | 192.04% |
| Cash from Operations | -11.32% | -10.65% | 19.33% | 41.61% | 51.31% |
| Capital Expenditure | 83.35% | 73.57% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 83.35% | 73.57% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 178.82% | 171.76% | 147.22% | 147.22% | 747.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -103.21% | -102.22% | -102.03% | -98.78% | -- |
| Cash from Financing | 188.36% | 180.37% | 152.26% | 152.62% | 652.67% |
| Foreign Exchange rate Adjustments | 14.46% | 104.34% | 97.09% | -470.44% | -121.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.40% | 111.62% | 108.91% | 108.50% | 70.61% |